Promising new agents in the treatment of non-small cell lung cancer

Martin J. Edelman; David R. Gandara

doi:10.1007/s002800050402

Promising new agents in the treatment of non-small cell lung cancer

Martin J. Edelman
, David R. Gandara

VA Medical Center

Research output: Contribution to journal › Review article › peer-review

45 Scopus citations

Abstract

A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

Original language	English
Pages (from-to)	385-393
Number of pages	9
Journal	Cancer Chemotherapy and Pharmacology
Volume	37
Issue number	5
DOIs	https://doi.org/10.1007/s002800050402
State	Published - 1996

Keywords

CPT-11
Docetaxel
Gemcitabine
Lung cancer
Topotecan
Vinorelbine
jPaclitaxel

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s002800050402

Cite this

@article{1a87da427092436fabbe3e061b798a27,

title = "Promising new agents in the treatment of non-small cell lung cancer",

abstract = "A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.",

keywords = "CPT-11, Docetaxel, Gemcitabine, Lung cancer, Topotecan, Vinorelbine, jPaclitaxel",

author = "Edelman, \{Martin J.\} and Gandara, \{David R.\}",

year = "1996",

doi = "10.1007/s002800050402",

language = "English",

volume = "37",

pages = "385--393",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "5",

}

TY - JOUR

T1 - Promising new agents in the treatment of non-small cell lung cancer

AU - Edelman, Martin J.

AU - Gandara, David R.

PY - 1996

Y1 - 1996

N2 - A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

AB - A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

KW - CPT-11

KW - Docetaxel

KW - Gemcitabine

KW - Lung cancer

KW - Topotecan

KW - Vinorelbine

KW - jPaclitaxel

UR - https://www.scopus.com/pages/publications/0030020182

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:A1996TV93900001&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1007/s002800050402

DO - 10.1007/s002800050402

M3 - Review article

C2 - 8599859

SN - 0344-5704

VL - 37

SP - 385

EP - 393

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 5

ER -

Promising new agents in the treatment of non-small cell lung cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this